Should an asymptomatic, non‑pregnant patient who tests positive for Ureaplasma and has no infertility work‑up, no immunocompromise, and is not scheduled for urologic or obstetric surgery be treated?

Do Not Treat Asymptomatic Ureaplasma-Positive Patients

Routine testing and treatment of asymptomatic individuals for Ureaplasma species is not recommended. Asymptomatic carriage is extremely common (40-80% of sexually active individuals), and the vast majority do not develop disease 1.

Evidence-Based Rationale

The strongest and most recent position statement from the European STI Guidelines Editorial Board (2018) explicitly states that routine testing and treatment of asymptomatic men and women for Ureaplasma urealyticum and Ureaplasma parvum are not recommended 1. This recommendation is based on several critical considerations:

Why Treatment Is Not Indicated

• High colonization rates without disease: Ureaplasma species colonize the urogenital tract of healthy individuals at rates of 40-80%, with most never developing symptoms or complications 1

• Lack of evidence for harm prevention: There is no clear evidence that detecting and treating asymptomatic Ureaplasma colonization prevents adverse outcomes or improves morbidity, mortality, or quality of life 1

• No impact on fertility in asymptomatic cases: Studies show no evidence that asymptomatic urogenital Ureaplasma infections adversely affect male or female fertility 2

• Risk of antimicrobial resistance: Unnecessary treatment contributes to antimicrobial resistance in Ureaplasma species, other STI pathogens, and the general microbiota 1

Clinical Context Matters

Recent research (2021) demonstrates that in nonpregnant women, Ureaplasma species are not associated with specific genital symptoms or clinical signs when other conditions are excluded 3. The study of 1,272 women found no association between Ureaplasma and symptoms after adjusting for bacterial vaginosis, candidiasis, and traditional STIs.

When Ureaplasma Testing Might Be Considered

Testing should only occur in symptomatic patients after excluding traditional STI pathogens:

For Men with Urethritis:

1. First exclude Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis
2. If testing is performed, use quantitative species-specific molecular tests
3. Only consider treatment if high bacterial load of U. urealyticum is documented 1
4. Note: U. parvum should not be treated even when detected 1

For Women with Symptoms:

1. Always test for and treat bacterial vaginosis first if present 1
2. Ureaplasma testing is generally not indicated even in symptomatic women 3

Critical Pitfalls to Avoid

The multiplex PCR trap: Many commercial multiplex PCR assays include Ureaplasma species alongside traditional STI pathogens. Detection does not equal disease and does not mandate treatment 1. The widespread availability of these tests has led to overdiagnosis and overtreatment.

Economic and clinical harm: Routine testing and treatment results in:

• Substantial economic costs for patients and healthcare systems
• Selection pressure for antimicrobial resistance
• Unnecessary anxiety and medicalization of normal colonization
• Potential harm to the microbiome 1

Special Populations Not Addressed

This recommendation applies specifically to asymptomatic, non-pregnant patients without:

• Active infertility work-up
• Immunocompromise
• Planned urologic or obstetric surgery

Different considerations may apply to pregnant women, neonates, or immunocompromised patients, though these are outside the scope of the current question.

Bottom Line

Do not screen for Ureaplasma in asymptomatic patients. If incidentally detected, do not treat. The evidence consistently shows we are doing more harm than good by detecting and treating these common colonizers in the absence of symptoms 1, 3, 2.